We report a patient who presented with swelling to the left submandibular region. Imaging studies revealed an expansive heterogeneous process. The patient underwent tumor resection and a biopsy confirmed the presence of a salivary duct carcinoma. Additional treatment included chemotherapy and the patient is currently receiving palliative and supportive care for advanced metastatic disease.
Introduction
Salivary duct carcinomas (SDCs) are rare and aggressive salivary gland tumors that predominantly occur between the fifth and sixth decades of life, predominantly in males. These head and neck tumors are locally aggressive, with early recurrence and distant metastases. Imaging studies are essential for preoperative staging and surgical planning. The treatment of choice is complete surgical resection and adjuvant radiation therapy.
Case Report
A 51-year-old man with a medical history of arterial hyperten-sion, obesity and smoking presented to the Ear, Nose and Throat clinic (ENT) complaining of progressive left submandibular swelling of 10 years duration. No pain or neurologic deficits were present. A sonography was performed that showed a solid hypoechogenic mass of 3.7 cm diameter, hyperechogenic calcium deposits within, and supracentimetric lymphadenopathies in II and V ipsilateral ganglionic levels ( Fig. 1) .
A neck-chest-abdomen computed tomography (CT) scan was performed, revealing an expansive-infiltrative, heterodense solid mass on the left submandibular gland, that measured 3.8 cm in diameter. The mass displayed irregular contours with central hypodense areas following intravenous contrast administration, suggestive of necrosis and calcifications within. The mass was invading the ipsilateral medial pterygoid and platysma muscles. Lymphadenopathy was observed with hypodense center in the left II-V ganglionic level as large as 11 mm. In addition, CT revealed the presence of nodules in the liver suggestive of metastatic disease (Fig. 2) .
A biopsy was performed under general anesthesia revealing an SDC. The Head and Neck Tumor Board reviewed the case, and recommended surgical excision and neck dissection. The postsurgical biopsy confirmed the presence of an SDC with infiltration of adjacent structures and positive lymphovascular/perineural invasion. Immunohistochemistry tests were positive for androgen receptor (AR+), Cerb-B2, GATA 3 and CK7 and negative for P63, KHMW, CK5/6 and P40 ( Fig. 3 ).
Follow-up by The Head and Neck Tumor Board where it was staged as a T3N2M1 resulted in the recommendation of palliative chemotherapy. He received six cycles of carboplatin and taxol, showing good tolerance and clinical local improvement. At the end of the treatment, neck-chest-abdomen-pelvis CT examinations were performed, revealing the presence of progressive liver nodules, and thoracic, lumbar, and sacral spine bone lytic lesions consistent of extensive metastatic disease ( Fig. 4 ). The patient was referred to the pain control and palliative care program.
Discussion
Salivary gland cancers are rare, accounting for < 1% of all malignancies [1, 2] and less than 5% of all head and neck malignancies. SDC accounts for approximately 0.2-2% of all salivary gland neoplasms. The first case of SDC was described by Kleinsasser et al in 1968 who described the distinct histologic similarity to ductal carcinoma of the breast, and was rec- ognized as a distinct entity by the World Health Organization (WHO) in 1991 [3] [4] [5] .
According to the 2017 WHO classification, SDC is an aggressive epithelial malignancy resembling high-grade mammary ductal carcinoma. It can occur de novo or as a carcinoma expleomorphic adenoma (CAxPA), the latter being a recent finding [6, 7] . "Low-grade SDC" and "SDC in-situ" of the former WHO classification are now named low-grade and highgrade intraductal carcinoma (IDC), respectively [8] .
The male to female ratio reported is approximately 3:1; in the fifth or sixth decades of life, with the average age of occurrence at 60 years, SDC is more common [9] [10] [11] , more common in the parotid gland (78-83%), whereas submandibular location (12%) and minor salivary glands (10%) are rarely affected. SDCs are made up of ductal and cribriform structures lined with epithelial cells with marked cytologic atypia. A Roman bridge like appearance and comedo-necrosis are typically observed in SDC, which strongly resembles ductal carcinoma of the breast [12] . The grading scheme that characterizes SDCs into four histologic patterns is as follows: sarcomatoid, mucinrich, micropapillary and basal-like [5] . The histopathologic diagnosis of SDC was based on hematoxylin and eosin stains and confirmed by immunohistochemical staining which have shown that SDC typically demonstrates epithelial markers, including cytokeratin, epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) [9, 12] .
Clinically, SDC is now well recognized as an aggressive malignancy, frequently presenting as stage IV disease [11] , present as a rapidly enlarging firm mass with a poor prognosis that is characterized by early lymph node invasion, distant me-tastases (brain, liver, adrenals, bone, skin and thyroid) (50%), high rate of local recurrence (50%) and ultimately a low survival rate, 3 years median [9, 13, 14] . Perineural and lymphatic invasion, further indicators of a poor prognosis, are frequently present in approximately 57% to 69% and 61% to 70% of patients, respectively [12] . Based on the study of SDC of the major salivary gland, tumor size > 3 cm and age > 50 years old have been proposed to be related to poor prognosis [15] .
SDC is usually described as an ill-defined, infiltrative mass with frequent necrosis on CT and magnetic resonance (MR) images [16] . The presence of calcification in an ill-defined salivary gland mass may be a good CT criterion that raises the possibility of SDC [17] . MR imaging has widely been used for differentiation of benign and malignant tumors of the salivary gland. The lower the signal intensity on T2-weighted images, the higher the possibility of high-grade malignancy [18] . According to Wang et al [19] , an apparent diffusion coefficient (ADC) value < 1.22 × 10 -3 mm 2 /s was one of the criteria for predicting malignancy. Yabuuchi et al [20] reported that a short time of peak enhancement, < 120 s, and a low washout ratio, < 30% (type B), on dynamic MR images were useful criteria for the diagnosis of malignant tumor. The focus in SDC that shows gradual upward enhancement on dynamic MR images, low ADC value and hypointensity on short-tau inversion recovery (STIR) and T2-weighted images may be a clue for making a diagnosis of SDC and separating SDC from the more common malignant salivary gland tumors such as mucoepidermoid carcinoma and adenoid cystic carcinoma [21] .
The treatment of choice is surgery according to the tumor site and its extent. Postoperative radiotherapy of 60 -66 Gy was given when any of the resection margins was positive or equivocal and/or lymph node metastasis was pathologically positive [3] . Chemotherapy is used for palliation in metastatic form of the tumor [8] . Molecularly targeted therapy against HER2 protein with anti-HER2 monoclonal antibodies has been suggested to be contributive as a therapeutic target for patients with HER2/neu-positive SDC [11, 13] . Tumor stage is an important indicator of overall survival and early cancer recurrence. The overall mean survival of these patients was reported to be approximately 36 to 56 months. The 5-year disease-free survival rates for stage I, II, III and IV SDCs were approximately 42%, 40%, 30% and 23%, respectively [13] . Local recurrence occurred in 48% of patients at 17.4 months after initial treatment. Distal metastases arose in 48% after 29 months [22] .
Conclusion
SDC is a rare and distinctive neoplasm with an aggressive behavior such as regional nodal and early distant metastasis, local recurrence and significant mortality. Although CT and MR imaging findings are nonspecific, the presence of calcifications on CT scans, low ADC value and marked low signal intensity on T2-weighted MR images may be radiologic features to suggest SDC. The treatment of choice is complete surgical excision and neck dissection; adjuvant radiation therapy is reserved for the extensive local infiltrative and lymph node invasion related to this malignancy (advanced form). HER2targeted therapies may therefore be a novel and effective future treatment choice for certain SDC patients. Systemic chemotherapy is reserved for unresectable locoregional recurrence or where there are distant metastases for palliative management.
